Thursday newspaper round-up: HSBC, RBS, Pharmacyclics
HSBC boss Stuart Gulliver apologised to MPs on Wednesday for the “unacceptable events” at the bank’s Swiss subsidiary following revelations about tax-avoidance activities in the mid-2000s, reports The Independent. He said it had caused “damage to trust and confidence” in the company.
ALPHABET-A
$193.95
13:09 07/01/25
Banks
4,961.13
16:44 09/01/25
DJ EURO STOXX 50
4,996.39
23:58 08/01/25
Dow Jones I.A.
42,635.20
04:30 15/10/20
FTSE 100
8,319.69
16:49 09/01/25
FTSE 350
4,563.23
16:44 09/01/25
FTSE All-Share
4,517.93
17:05 09/01/25
HSBC Holdings
802.50p
17:15 09/01/25
Iberdrola
€13.74
18:16 09/01/25
IBEX 35
11,899.30
18:39 09/01/25
Johnson & Johnson
$142.27
11:04 07/01/25
Nasdaq 100
21,180.96
12:15 07/01/25
NATWEST GROUP
385.00p
16:45 09/01/25
RBS’s chief executive Ross McEwan is to hand back £1m of his annual pay package, saying he did not want to receive the “role-based” shares incentive, according to The Guardian.
US cancer drugs manufacturer Pharmacyclics is said to be considering a sale that could value it at $19bn, the Financial Times said. According to the paper’s sources, Johnson & Johnson is exploring a deal with the company.
According to the Wall Street Journal, Google and merged its European operations into a single business “to better align the business with large customers and develop more unified responses to rising regulatory pressure in the region”.
Terra Firma is planning to start a sale of its European cinema chain, Odeon & UCI Group, at the end of the year, reports The Telegraph. The deal could be worth £1bn.
Iberdrola, the Spanish power utility group, has agreed to buy US power and gas distributor UIL Holdings for $52.83 a share, valuing the group at $3bn, the Wall Street Journal reports.
Russia has threatened to disrupt gas supplies to Europe as it demanded immediate advance payments from Ukraine, writes The Times.